The American College of Physicians (ACP) has issued a strong call for significant reforms to the regulation of dietary supplements, arguing that the current framework, governed by the Dietary Supplement Health and Education Act (DSHEA) of 1994, poses an unacceptable risk to public health. In a comprehensive position paper published in the Annals of Internal Medicine, the ACP outlines a series of recommendations aimed at modernizing oversight of the rapidly growing multi-billion dollar industry. The organization contends that the existing regulations are insufficient, leading to a market where products are not adequately evaluated for safety and efficacy before reaching consumers.
The ACP’s stance highlights a critical tension between the recognized benefits some supplements can offer and the inherent vulnerabilities in the current regulatory landscape. "Under the current regulatory framework, supplements are not evaluated for their safety before going to market, unlike drugs and food additives," stated Jan Carney, M.D., ACP President, underscoring the fundamental difference in regulatory approach. This lack of premarket scrutiny, according to the ACP, leaves consumers exposed to potential harm from unproven ingredients, undisclosed contaminants, and dangerous interactions with prescribed medications.
The ACP’s position paper details ten key recommendations, many of which focus on enhancing the capabilities and funding of regulatory bodies like the U.S. Food and Drug Administration (FDA). Among these, several proposals are poised to have the most profound impact on the dietary supplement industry. These include a push for mandatory premarket safety assessments, improved postmarket surveillance systems, and clearer guidelines for substantiating health claims made by manufacturers.
The Case for Regulatory Modernization: Unpacking the ACP’s Concerns
The core of the ACP’s critique centers on two primary deficiencies within the existing DSHEA framework: the absence of mandatory premarket safety evaluation and an over-reliance on postmarket surveillance. The organization points to a significant disconnect between supplement usage and healthcare provider recommendation, noting that while over 50% of American adults report taking dietary supplements, a mere 25% do so under the guidance of a healthcare professional. This gap, the ACP argues, exacerbates the risks associated with unsupervised supplement use.
Further amplifying these concerns are the statistics on adverse events. Between 2004 and 2021, the FDA’s Center for Food Safety and Applied Nutrition (CFSAN) received over 79,000 adverse event reports linked to dietary supplement consumption. While this figure represents reported incidents and not necessarily the full scope of harm, it serves as a stark indicator of potential issues. "Although some dietary supplements, principally vitamins and minerals, are thoroughly tested for safety and efficacy… many others are not backed by strong scientific evidence or contain unsafe ingredients," the authors of the position paper emphasized.
The ACP’s recommendations extend to improving the infrastructure for tracking and managing supplement-related health issues. A key proposal involves the integration of dietary supplement databases with electronic health records (EHR) systems. Such integration would equip healthcare professionals with better tools to advise patients, identify potential contraindications, and monitor for adverse reactions, especially given that current research suggests physicians may possess limited knowledge regarding the vast array of supplements available on the market. "Skewed public perception of the safety of supplements and low rates of reporting their use to physicians and other healthcare professionals only contribute to making the public more at risk for severe adverse outcomes," Carney asserted.
Defining "Strong Scientific Evidence" in the Supplement Landscape
A critical aspect of the ACP’s recommendations hinges on the definition of "strong scientific evidence" required to support health claims made by supplement manufacturers. The organization clarifies that this standard necessitates "peer-reviewed clinical trials demonstrating the safety and efficacy of a supplement/dietary ingredient for claims made by the manufacturer." Furthermore, the ACP emphasizes the importance of research into pharmacokinetics, pharmacodynamics, and optimal dosages of dietary ingredients as integral components of a robust evidence base.
This definition aligns with, and in some ways expands upon, the standards employed by many within the dietary supplement industry itself when substantiating claims. Susan Hewlings, Ph.D., co-founder of Substantiation Sciences and SVP of scientific affairs at Radicle Sciences, elaborated on the criteria for scientific substantiation. She noted that essential, non-negotiable elements include ensuring the study dose matches the labeled dose, the tested ingredient corresponds to what is found in the product, the study population accurately reflects the target demographic for the claim, and the endpoints measured are relevant and assessed using validated methods. Hewlings also stressed the importance of appropriate statistical analyses, accurate interpretations, and thorough toxicology assessments, both preclinical and in humans. "Safety evidence should go beyond an absence of reported harm," she added, highlighting the need for proactive safety evaluations rather than merely reacting to reported incidents.
The increasing consumer demand for transparency and the pervasive influence of social media have spurred greater research and scrutiny within the dietary supplement sector. This evolving landscape underscores the need for clear, scientifically grounded evidence to support product claims and ensure consumer safety.
Industry Organizations Respond: Divergent Views on Regulatory Reform
The ACP’s position paper has naturally drawn reactions from key industry organizations, revealing a spectrum of agreement and significant points of contention. The Council for Responsible Nutrition (CRN), a trade association representing the dietary supplement industry, acknowledged common ground with the ACP on certain objectives, such as improving transparency and ensuring product quality. However, CRN fundamentally disagreed with the ACP’s conclusion that these goals necessitate replacing DSHEA with a pharmaceutical-style premarket approval system.
"Where we fundamentally disagree is the paper’s conclusion that these goals require replacing DSHEA with a pharmaceutical-style premarket approval system for dietary supplements," CRN stated in its official response, while expressing support for mandatory product listing. The organization argued that many of the issues highlighted by the ACP are already prohibited under existing law. CRN’s perspective is that the identified problems do not signify a failure of DSHEA itself but rather a need for more rigorous enforcement against companies that violate its provisions.
Daniel Fabricant, Ph.D., CEO and president of the Natural Products Association (NPA), characterized the ACP’s position paper as "hyperbole." He asserted that the medical community often lacks a thorough understanding of how the dietary supplement industry is regulated and suggested a disconnect between physicians and the industry. Fabricant pointed to existing resources, such as the National Institutes of Health’s Dietary Supplement Label Database (DSLD), as valuable tools for healthcare professionals.
The NPA’s statement further emphasized the role of dietary supplements in promoting consumer self-care and improved health outcomes. "Consumers who use supplements and engage in self-care achieve better health outcomes," Fabricant stated. He concluded by criticizing the ACP’s stance as "tone-deaf to the growing role of dietary supplements as part of a healthy lifestyle focused on nutrition and prevention of disease," and pledged the NPA’s opposition to any proposals that would dismantle the existing DSHEA framework.
Broader Implications and the Path Forward
The debate ignited by the ACP’s position paper reflects a broader societal conversation about consumer health, the role of supplements, and the adequacy of regulatory oversight. The ACP’s recommendations, if implemented, could lead to a more rigorous and science-driven market for dietary supplements. This could involve increased compliance costs for manufacturers, potentially leading to fewer products on the market but a greater assurance of safety and efficacy for consumers.
For consumers, enhanced regulation could mean greater confidence in the products they choose, reducing the risk of adverse events and misleading claims. Healthcare providers would be better equipped to integrate supplement advice into patient care, fostering a more holistic approach to wellness.
Conversely, industry groups like CRN and NPA argue that overly stringent regulations, particularly a premarket approval system akin to pharmaceuticals, could stifle innovation, increase costs prohibitively, and limit consumer access to beneficial products. They advocate for a focus on enforcement and education within the existing DSHEA structure.
The timeline for potential regulatory changes remains uncertain. The ACP’s paper serves as a significant advocacy document, aiming to influence policymakers and public opinion. Future developments could involve legislative proposals in Congress, FDA rulemakings, or continued dialogue between the medical community, industry stakeholders, and consumer advocacy groups. The ongoing discussion underscores the complex balance required to protect public health while supporting a legitimate and evolving dietary supplement market. The emphasis on scientific substantiation, transparency, and robust oversight is likely to remain central to these future debates.
